News

January 2015: Action Duchenne announce £55,000 funding for biomarker panel research project

We are delighted to announce that the project titled ‘Definition of pharmacodynamics biomarker panel in a Phase 2a clinical trial of VBP15 in DMD’ has successfully completed our peer-review process. The aim of this proposal is to address the increasing concern that there aren’t enough Duchenne patients available to adequately satisfy the needs of the drug development programs in a timely manner. An acknowledged approach towards this end is the development of robust pharmacodynamics biomarker panels. These allow testing of the effects of a drug on much more acute time frames (2-4 weeks), and are considered more quantitative and less subject to bias.